Cardioprotective potential of *Dendrobium officinale* Kimura et Migo against myocardial ischemia in mice

MENG-MENG DOU\(^1\), ZHI-HAO ZHANG\(^1\), ZHU-BO LI\(^1\), JIE ZHANG\(^2\) and XIAO-YAN ZHAO\(^1\)

\(^1\)Department of Pharmacology, College of Pharmaceutical Sciences, Southwest University, Chongqing 400716; \(^2\)Department of Neurology, The Ninth People's Hospital of Chongqing, Chongqing 400700, P.R. China

Received October 2, 2015; Accepted September 14, 2016

DOI: 10.3892/mmr.2016.5789

**Abstract.** *Dendrobium officinale* Kimura et Migo has been used for thousands of years to promote body fluid production; however, little is currently known regarding its effects on the heart. The present study aimed to explore the cardioprotective potential of the water extract of *Dendrobium officinale* Kimura et Migo (DOE) on myocardial ischemia in mice. A mouse model of myocardial ischemia was induced following ligation of the left anterior descending coronary artery. Prior to the operation, mice were administered a vehicle or DOE for 2 weeks. Following the operation, ST elevation was measured. To estimate the extent of myocardial damage, infarct size analysis and histopathological examination were performed. The activities of cardiac marker enzymes [creatine kinase (CK)-MB and lactate dehydrogenase (LDH)] and antioxidative indicators [malondialdehyde (MDA) and superoxide dismutase (SOD)] were also analyzed to explore the underlying mechanisms. Treatment with DOE decreased infarct size and the number of apoptotic cardiomyocytes; reduced serum CK-MB, LDH and MDA activities; and increased SOD levels. According to western blotting, DOE conferred protection against myocardial ischemic injury via the regulation of Meis1 expression. These results indicated that DOE may exert potential cardioprotective effects against myocardial ischemia; these effects may be associated with its antioxidant activity, and its ability to inhibit cardiac cell apoptosis and to regulate Meis1 expression.

**Introduction**

Cardiovascular diseases (CVDs), particularly ischemic heart disease, are the primary cause of disability and mortality worldwide. The World Health Organization estimated that 17.5 million people succumbed to CVDs in 2012, and 7.4 million deaths were attributed to ischemic heart disease (1). The pathogenesis of myocardial ischemia, which is caused by atherosclerotic plaques or coronary artery occlusion (2), is considered to be multifactorial, and is associated with oxidative stress (3), mitochondrial dysfunction (4) and apoptotic cascade activation (5). Conversely, antioxidants may decrease cellular injury and apoptosis in ischemic hearts through radical-scavenging activities (6).

Natural products-based therapeutic strategies have been suggested as a potential option for the treatment of patients with myocardial ischemia (7). *Dendrobium officinale* Kimura et Migo (Orchidaceae family) is a prized traditional Chinese medicine, which has been used clinically to promote body fluid production and maintain gastric tonicity in China and Southeast Asia (8). *Dendrobium officinale* has been reported to possess diverse pharmacological properties, including anti-inflammatory (9), immunomodulatory (10), neuroprotective (11) and antitumor (12) activities. *Dendrobium officinale* polysaccharides, which are a potential candidate for the treatment of Sjögren's syndrome (13), were able to suppress the overexpression of proinflammatory cytokines, including tumor necrosis factor-α, interleukin (IL)-1β and IL-6, in a mouse model of Sjögren's syndrome, and inhibited apoptosis by downregulating the expression of caspase-3 and decreasing the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio (9). *Dendrobium officinale* polysaccharides also possess immunomodulatory activity *in vivo* and *in vitro*, which is mediated by nitric oxide (10). Furthermore, dendrocandins extracted from *Dendrobium officinale* have been reported to promote neurite outgrowth in PC12 cells (14). Considering the antiaggregation activity of other *Dendrobium* species (15), the present study hypothesized that the water extract of *Dendrobium officinale* (DOE) may exert cardioprotective effects against myocardial ischemia.

The homeodomain protein Meis1 is a three amino acid loop extension transcription factor, which participates in various physiological processes, including growth, proliferation and prevention of the accumulation of reactive oxygen.
species (16). Specifically, the Meis1/pre-B-cell leukemia homeobox 1/homeobox A9 complex is able to activate oncogenic genes, resulting in cell hyperproliferation (17). Meis1 is also required to establish definitive hematopoiesis in the mouse embryo, and its deletion in vivo may lead to agenesis of the megakaryocyte lineage and localized defects in vascular patterning (18). In terms of normal cardiac development, Meis1 acts as a regulator of cardiomyocyte cell cycle arrest and a potential transcriptional regulator of neonatal heart regeneration (19).

The present study aimed to evaluate the cardioprotective effects of DOE in vivo. Briefly, myocardial ischemia was induced in mice following ligation of the left anterior descending coronary artery (LAD). Subsequently, the effects of water-soluble components of *Dendrobium officinale* were investigated on myocardial injury, and the potential underlying mechanisms against cardiomyopathy were evaluated. The results suggested that pretreatment with DOE significantly decreased infarct size; reduced creatine kinase (CK)-MB and lactate dehydrogenase (LDH) levels in serum; and attenuated cardiac oxidative damage.

### Materials and methods

**Chemicals and methods.** CK-MB (cat. no. H197), LDH (cat. no. A020-1), total superoxide dismutase (SOD; cat. no. A001-1) and malondialdehyde (MDA; cat. no. A003-1) diagnostic agents were obtained from Nanjing Jiancheng Bioengineering Research Institute (Nanjing, China). Meis1 antibody (cat. no. BS3488) was obtained from Bioworld Bioengineering (Wuhan, China). GAPDH polyclonal primary antibody (cat. no. 10494-1-AP) and goat anti-rabbit horseradish peroxidase-conjugated immunoglobulin G secondary antibody (cat. no. SA00001-2) were purchased from Wuhan Sanying Biotechnology (Wuhan, China). All other reagents used were of commercial analytical grade.

**DOE preparation.** The dry stems of *Dendrobium officinale* were purchased from Xi’an Xiaocao Botanical Development Co., Ltd. (Xi’an, China). The voucher specimens were deposited at Southwest University (Chongqing, China). Briefly, the dry stems were ground into a fine powder through a 100-mesh filter. The powdered materials (100 g) were pre-extracted using petroleum ether and the residues were then extracted three times using hot distilled water. The crude extracts were filtered through a 0.22 µm microporous membrane, concentrated via the alcohol precipitation method and centrifuged at 625 × g for 10 min. The plant extracts were then dried by lyophilization, and 23.5 g powder was produced. The DOE predominantly consisted of polysaccharide, and the concentration of polysaccharide was determined by the phenol-sulfuric acid method to be 97.4%.

**Experimental animals.** A total of 60 Kunming male mice (age, 4 weeks; weight, 22±2 g) were purchased from Chongqing Tengxin Bio-technology Co., Ltd. (Chongqing, China). The present study was carried out according to recommendations of the National Institutes of Health Guide for the Care and Use of Laboratory Animals (2015). In addition, the experiments were approved by the Ethical Committee for Animals of Southwest University. The mice were housed in standard conditions: Humidity, 50%; temperature, 25±2°C, under a 12:12 h light/dark cycle, with ad libitum access to normal food and tap water. Mice were allowed to acclimate to the environment for 1 week prior to experimentation.

**Experimental procedure.** Mice were randomly assigned to five groups (n=10/group): Sham group, model group, and LAD + DOE pretreatment groups (75, 150 and 300 mg/kg DOE; oral administration). DOE was dissolved in distilled water. Mice were administered normal saline (10 ml/kg) or DOE (75, 150 or 300 mg/kg) intragastrically once daily for 2 weeks. Subsequently, the mice were subjected to coronary artery ligation; LAD occlusion was performed as previously reported (20,21). Briefly, the left chest cavity of the mice was opened and the heart was exposed following anesthetization with sodium pentobarbital (40 mg/kg, i.p.). Subsequently, in the model and LAD + DOE pretreatment groups, 7-0 silk was used to ligate the LAD for 24 h, after which the heart was returned to its normal position and the thoracic cavity was closed. In the sham group, 7-0 silk was passed through the LAD, without ligation. After 24 h, mice were sacrificed by an overdose of pentobarbital sodium (100 mg/kg), and blood and heart samples were collected.

**Electrocardiogram (ECG) record.** The lead II ECG was recorded using the BL-420F biological function experiment system (Chengdu Taimeng Technology Co. Ltd., Chengdu, China). Significant ECG changes, including elevation of the ST segment and widening of the QRS complex, indicated successful coronary occlusion.

**Determination of infarct size.** A total of 24 h after ischemia, the hearts were collected and dissected at 1.2 mm cross-section. Subsequently, the heart sections were stained with 1% triphenyl tetrazolium chloride (TTC) for 15 min at 37°C in 0.2 M phosphate-buffered saline (22). The viable myocardium was stained red, whereas the infarcted tissue remained pale. Images were captured and the infarct size was analyzed using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA).

**Determination of serum CK-MB, LDH, SOD and MDA activity.** Blood samples were collected and were centrifuged at 625 x g for 10 min at 4°C to obtain serum samples. The CK-MB, LDH, SOD and MDA activity levels in the serum samples were determined using commercially available kits according to the manufacturer's protocols.

**Histopathological examination.** Heart tissues harvested from the mice were washed immediately with ice-cold saline. The biopsies were then fixed in 4% neutral paraformaldehyde and were embedded in paraffin. Heart tissues were cut into 5 µm sections, which were stained with hematoxylin and eosin (H&E) for 90 min at room temperature. Morphological evaluation and observation were performed under a light microscope.

**Terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay.** TUNEL assays were performed as previously reported (23). The total number of TUNEL-positive cardiomyocyte nuclei in the infarcted zone was counted.
Individual nuclei were visualized at a magnification of 400x (Olympus CKX41; Olympus Corporation, Tokyo, Japan), and the percentage of apoptotic nuclei (apoptotic nuclei/total nuclei) was calculated in six randomly selected fields per section and averaged for statistical analysis.

Western blotting. Heart tissues were lysed in radioimmunoprecipitation assay buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 1% SDS, 1 mM phenylmethylsulfonyl fluoride], and concentration was determined using the bicinchoninic acid method. Heart tissue lysates (100 µg) were separated by 12% SDS-PAGE, and the proteins were electrophoretically transferred to polyvinylidene difluoride membranes. After blocking non-specific binding sites for 2 h with 5% dried skim milk at room temperature, the membranes were individually exposed to primary antibodies (anti-Meis1, 1:6,000; anti-GAPDH, 1:10,000) at 4˚C overnight. The membranes were subsequently incubated for 2 h at room temperature with HRP-conjugated secondary anti-rabbit antibodies. The immunoreactive proteins were detected using an enhanced chemiluminescence reagent (Advansta Inc., Menlo Park, CA, USA). The proteins

Figure 1. ECG recording in each group. The lead II ECG was recorded using a BL-420F biological function experiment system. (A) Sham group. (B) Model group. (C) DOE 75 mg/kg group. (D) DOE 150 mg/kg group. (E) DOE 300 mg/kg group. (F) ST segment changes in the ECG. Data are presented as the mean ± standard deviation (n=10). *P<0.01 vs. the sham group; †P<0.05, ‡P<0.01 vs. the model group. ECG, electrocardiogram; DOE, water extract of Dendrobium officinale.
Effects of DOE on ECG parameters. The Lead II ECG is presented in Fig. 1. Marked elevation of the ST segment was detected in the myocardial ischemia model group, whereas a normal ECG was observed in the sham group. Ischemia-induced alterations to the ECG were significantly ameliorated by pretreatment with DOE, as compared with in the model group.

Effects of DOE on infarct size. To evaluate infarct size, TTC staining was performed. The cross-section of the heart stained with TTC is presented in Fig. 2A. As shown in Fig. 2B, DOE markedly decreased infarct size compared with the model group. A modest reduction in infarct size was detected in mice treated with 75 mg/kg DOE (5.6% decrease). Notably, pretreatment with 150 mg/kg DOE more significantly reduced infarct size (10.0% decrease).
Effects of DOE on serum CK-MB and LDH levels. As shown in Fig. 3, CK-MB and LDH activities, which are indicators of myocardial ischemia, were significantly increased in the myocardial ischemia model group compared with the sham group. Conversely, pretreatment with DOE for 2 weeks decreased myocardial CK-MB and LDH release. Furthermore, the most obvious reduction was exhibited in mice pretreated with the middle dose of DOE (150 mg/kg). However, there was no marked difference in the alterations in CK-MB and LDH levels between the middle dose group (150 mg/kg) and the high dose group (300 mg/kg).

Effects of DOE on serum MDA and SOD levels. Myocardial ischemia is associated with oxidative stress (24); therefore, MDA and SOD levels were measured in the present study. As shown in Fig. 4, MDA activity was markedly increased in the model group, whereas pretreatment with DOE for 2 weeks decreased serum MDA levels. Furthermore, the most obvious decrease was observed in the middle dose group (150 mg/kg). Conversely, SOD activity was reduced in the model group compared with the sham group, whereas SOD levels were increased by pretreatment with DOE, as compared with in the model group. However, no significant change was detected in serum SOD levels between the low dose DOE group (75 mg/kg) and the model group.

Effects of DOE on histopathological alterations in myocardial tissue. Histopathological evaluation of cardiac tissue was conducted using H&E staining, as presented in Fig. 5. The cardiac tissue in the sham group exhibited a clear structure without infiltration of inflammatory cardiomyocytes (Fig. 5A). However, myocardial structural abnormalities, including cytoplasmic vacuolization, cardiomyocyte necrosis and inflammatory infiltration, were detected in the model group (Fig. 5B). Conversely, the presence of necrotic cardiomyocytes was rare, and vacuolization and myofibrillar loss were almost undetectable following pretreatment with DOE (Fig. 5C-E).

Effects of DOE on myocardial apoptosis. Apoptotic alterations in cardiac tissue and the percentage of TUNEL-positive cells are presented in Fig. 6. As shown in Fig. 6A, TUNEL-positive cells were rarely detected in the sham group. However, the number of TUNEL-positive cells was markedly increased in the myocardial ischemia model group (Fig. 6B). The number of TUNEL-positive cells was significantly decreased (42.5±12.4, 37.3±1.6 and 18.2±4.5%) by pretreatment with DOE (75, 150 and 300 mg/kg) compared with the model group (54.2±7.5%).

Effects of DOE on the expression of Meis1. To determine the underlying mechanism of DOE, the protein expression levels of Meis1 were assessed by western blotting. The
results presented in Fig. 7 indicate that the expression levels of Meis1 were significantly decreased in the model group compared with the sham group. Conversely, pretreatment with DOE (75 and 150 mg/kg) markedly upregulated the expression of Meis1.

Discussion

The present study demonstrated that pretreatment with DOE significantly inhibited ST segment elevation, reduced infarct size and attenuated cardiomyocyte apoptosis. Furthermore, DOE prevented CK-MB and LDH release, decreased serum MDA levels, increased serum SOD levels and upregulated the protein expression levels of Meis1. These results suggested that DOE may serve a protective role against ischemic cardiomyopathy, and may be considered a potential clinical agent in the attenuation and prevention of ischemic injury.

ECG is an important clinical tool used to evaluate heart function. ST segment monitoring is sensitive during the development of ischemia (25). ST segment elevation, which is a reliable biomarker for the diagnosis of myocardial ischemia, is associated with continuous damage to the cell membrane (26). In the present study, ST segment elevation was observed in the model group; however, ST segment elevation was alleviated by pretreatment with DOE. These data indicated that DOE may ameliorate cardiac ischemia.
the SOD, which is an antioxidant enzyme, is beneficial in against myocardial ischemia by reducing lipid peroxidation.

Notably, the elevated levels of serum CK-MB and LDH in the model group were significantly reduced by pretreatment with DOE. These results indicated that DOE may attenuate damage to cardiomyocytes, reduce the leakage of cardiac markers and decrease inflammatory cell recruitment. Apoptosis had been observed in cardiac pathologies, including hypoxia, ischemia reperfusion and myocardial ischemia (35). In the present study, TUNEL assays demonstrated that pretreatment with DOE decreased the degree of apoptosis in the heart. These data suggested that DOE may attenuate cardiac injury through inhibiting myocardial apoptosis.

Meis1 is a critical transcriptional regulator in cardiomyocyte proliferation, which may be considered a potential therapeutic target for heart regeneration (19). Stankunas et al examined cardiac development in mice lacking Meis1 and demonstrated that embryos without Meis1 displayed subcutaneous hemorrhage and died between embryonic day 14.5 and 15.5, confirming that Meis1 is essential for cardiac development (35). In the present study, the expression levels of Meis1 were decreased in the model group. However, this decrease was markedly ameliorated by pretreatment with DOE (75 and 150 mg/kg); this may be a potential mechanism underlying the protective effects of DOE against myocardial ischemia. Therefore, Meis1 may be a novel therapeutic target for the development of anti-ischemia drugs. However, further studies are required to confirm this hypothesis.

In conclusion, the present study demonstrated that DOE possessed cardioprotective potential against LAD ligation-induced myocardial ischemia. The underlying mechanism is possibly associated with restoration of antioxidant enzyme activity, inhibition of apoptosis and upregulation of Meis1 expression. These findings may be beneficial for patients with myocardial ischemia; however, further studies are required to elucidate the precise molecular mechanisms underlying the effects of DOE.

Acknowledgements

The present study was supported by the Chongqing Science and Technology Commission (no. cstc2016jcyjA0926), the Fundamental Research Funds for the Central University (nos. XDJK2014B024 and XDJK2016E137), and the Innovative Project on Designing and Screening Drug Candidates of Chongqing (no. cstc2015zdcy-<f>ztxx120003</f>).</p>

<h3>References</h3>


